Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685151 | 0.91 | CCND1 (0.39) | MAPKAPK2RIPK1LRRK2 | |
| SCHEMBL1685337 | 0.88 | MAPKAPK5 (0.44) | JAK1MAPKAPK2NAMPTPLA2G2ALRRK2 | |
| SCHEMBL1685123 | 0.85 | MAPKAPK2 (0.34) | MAPKAPK2DRD3RIPK1ALK | |
| SCHEMBL1685148 | 0.85 | HRH3 (0.38) | MAPKAPK2RIPK1 | |
| SCHEMBL1685204 | 0.84 | RIPK1 (0.43) | JAK1RIPK1 | |
| SCHEMBL10166814 | 0.82 | DRD2 (0.36) | JAK1MAPKAPK2NAMPTDRD3DRD2 | |
| SCHEMBL1685173 | 0.81 | MKNK1 (0.43) | — | |
| SCHEMBL14162723 | 0.80 | NAMPT (0.36) | JAK1NAMPTDRD3DRD2THRB | |
| SCHEMBL12618775 | 0.80 | MAPKAPK5 (0.46) | JAK1MAPKAPK2NAMPTDRD3DRD2 | |
| SCHEMBL3881243 | 0.80 | CDK1 (0.39) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | JAK1 1529/4885MAPKAPK2 37/4885NAMPT 526/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | JAK1 1529/4885MAPKAPK2 37/4885NAMPT 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.